- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00553657
The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
October 13, 2010 updated by: GlaxoSmithKline
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients With Idiopathic Overactive Bladder
The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.
Study Overview
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Randwick, Sydney, New South Wales, Australia, 2031
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must report frequency, defined as at least 8 micturitions per 24 hour period.
- Eligible patients must have signed the informed consent and must meet all inclusion and exclusion criteria as determined during the screening visit.
Exclusion Criteria:
- Any abnormality identified on the screening examination or any other medical condition or circumstance making the patient unsuitable for participation in the study based on the Investigator's and Medical Monitor's assessment
- Any contraindication to Detrol LA or other anti-muscarinic medications
- Inability to consume 10 cc/kg of fluid within 30 minutes
- Regular alcohol consumption averaging ³7 drinks/week for women (1 drink = 100mL of wine or 285mL of beer or 30mL of hard liquor)
- Positive urine drug or alcohol at screening at screening
- Average blood pressure measurements systolic ≥140 or diastolic ≥90 at screening at screening
- QTcB value ≥ 450 msec at screening
- Poorly-controlled diabetes mellitus or hypertension, as evidenced by a change in medication within the 2 months prior to initiation of the study
- History of urinary retention or gastric retention
- Known history of narrow-angle glaucoma
- History of QT prolongation
- Known reduction in hepatic or renal function
- Concomitant Use of loop diuretics (eg. Furosemide)
- Concomitant use of a medication that is a potent inhibitor of CYP3A4
- Class IA or Class III antiarrhythmic medications
- Patient is unable and/or unwilling to adhere to Lifestyle Guidelines
- For women of child bearing potential, a positive serum β-hCG at screening or pre-dose, or an unwillingness to agree to adequate contraception from the time of screening until the completion of the study:
- Positive for hepatitis C antibody, hepatitis B surface antigen or HIV at screening.
- Presence of urinary tract infection within 4 weeks of screening.
- Post-void residual of >150 mL (bladder ultrasound).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variability of change from baseline in mean volume per void measured on 3 consecutive days.
Time Frame: 3 consecutive days
|
3 consecutive days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline in volume voided per void. Percent and actual change from baseline in maximum volume voided, number of micturitions, number of incontinence episodes, number of urgency episodes, and time to first void on 3 consecutive days.
Time Frame: 3 consecutive days
|
3 consecutive days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2007
Primary Completion (ACTUAL)
January 1, 2008
Study Completion (ACTUAL)
January 1, 2008
Study Registration Dates
First Submitted
November 2, 2007
First Submitted That Met QC Criteria
November 2, 2007
First Posted (ESTIMATE)
November 4, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
October 26, 2010
Last Update Submitted That Met QC Criteria
October 13, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Tolterodine Tartrate
Other Study ID Numbers
- BKB105190
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on DETROL LA (drug)
-
Hospices Civils de LyonCompletedPotentially Inappropriate MedicationsFrance
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
NovartisProcter and GambleCompleted
-
National Institute of Allergy and Infectious Diseases...Not yet recruitingPregnancy | HIV-1-infection | PostpartumUnited States, South Africa
-
Lu WangRecruitingPain Control | Regional Anesthesia | Liver Tumors | Microwave AblationChina
-
Philip Morris Products S.A.CompletedVaping | Nicotine AbsorptionUnited States
-
Association of Urologic Oncology (AUO)Eli Lilly and CompanyCompleted
-
University of California, San FranciscoCompletedUrge Incontinence | Urinary Incontinence, UrgeUnited States
-
Riyadh Colleges of Dentistry and PharmacyCompletedVital Signs Changes During Dental ProceduresSaudi Arabia
-
Kaohsiung Medical UniversityCompleted